EMDC

10 Things I’m Tired of Hearing About Pharma Social Media I especially liked this part: 8. “There is a need for useful healthcare-related social media tools/content/platforms/communities that pharma companies can help fill.” What? There are so many things wrong with this, I’m not sure where to begin. I’ll just cover two though for the sake [...]

The Beginner’s Guide to Pharma Social Media TONS of resources here. Including a response to the oft-asked “What about adverse events?” question.

FDASM – “Everything about the FDA, Internet, & Social Media” It’s an aggregator of information about the FDA, it’s use of social media, and it’s regulation of social media use by the industries it oversees.

Eye on FDA: What We Didn’t Hear at the FDA Part 15 Meeting on Social Media We heard from far too few pharma companies, and far too many bloggers. What was missing? What anyone should be doing in the meantime, what’s the process going forward, and what (if anything) is going on in Europe.

Rich Meyer says pharma marketers don’t even know what to do with the web traffic data they already have much less how to integrate social media into the mix, which is ironic considering how much research goes into pharma industry decision-making.

Federal Register: FDA Announcement of Social Media Hearing [Federal Register: September 21, 2009 (Volume 74, Number 181)] [Notices] [Page 48083-48088] From the Federal Register Online via GPO Access [wais.access.gpo.gov] [DOCID:fr21se09-58] ———- DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2009-N-0441] Promotion of Food and Drug Administration-Regulated Medical Products Using the Internet [...]

Common Sense Media Group: The 5 Myths Surrounding the FDA and Social Media Must read. He takes a pretty pessimistic view. Basically, don’t expect FDA action any time soon and don’t expect any radical changes. (via ePharma Rx)

Eye on FDA: What Companies Should Do Between Now and The Part 15 Hearing on Social Media A good read all the way through. He has advice for individual companies and for industry associations. And this: At the FDLI conference held earlier this week in Washington, both Dr. Janet Woodcock and Tom Abrams affirmed that [...]

AdAge: FDA to Hold Public Hearings on Big Pharma’s Social-Media Use The U.S. Food and Drug Administration will hold a two-day public hearing in November on how pharmaceutical companies use the web and social-media tools to market their products, the first step in a long overdue process that will finally establish guidelines for how drug [...]

“Use of internet-based social media such as Facebook and Twitter can pose compliance risks for drug companies, experts agree.” — I’ll say this: Any time anyone who is employed by a drug (or device, or biotech) company opens their mouth, it’s a compliance risk. Regulated companies can and should use social media channels to market themselves instead of their products.